| REGENXBIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US75901B1070 / A140E0 |
| RB0 (Frankfurt) / RGNX (NASDAQ) |
| FRA:RB0, ETR:RB0, RB0:GR, NASDAQ:RGNX |
| - |
| https://www.regenxbio.com.. |
|
Regenxbio Inc. is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies to treat genetic disorders through its proprietary NAV Technology Platform. This platform utilizes recombinant adeno-associated ..
>Volltext.. |
| 442.59 Mio. EUR |
| 468.52 Mio. EUR |
| 145.56 Mio. EUR |
| -124.33 Mio. EUR |
| -165.58 Mio. EUR |
| -3.21 EUR |
| 222.49 Mio. EUR |
| 29.43 Mio. EUR |
| - |
| 1.95 |
| 80.28% |
| 24.75% |
| - |
| - |
| - |
| REGENXBIO |
| 14.05.26 |
|
||||
|
||||
|
||||
|
||||
|